Select Publications
Journal articles
2024, 'The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, Australia', Pharmacoepidemiology and Drug Safety, 33, http://dx.doi.org/10.1002/pds.5887
,2024, 'Antipsychotic use during pregnancy and risk of specific neurodevelopmental disorders and learning difficulties in children: a multinational cohort study', eClinicalMedicine, 70, http://dx.doi.org/10.1016/j.eclinm.2024.102531
,2023, 'Expanded access to publicly subsidised lisdexamfetamine treatment for adults with attention-deficit/hyperactivity disorder: An interrupted time-series analysis', Australian and New Zealand Journal of Psychiatry, 57, pp. 1073 - 1076, http://dx.doi.org/10.1177/00048674231170556
,2023, 'Patterns of attention deficit hyperactivity disorder medicine use in the era of new non-stimulant medicines: A population-based study among Australian children and adults (2013–2020)', Australian and New Zealand Journal of Psychiatry, 57, pp. 675 - 685, http://dx.doi.org/10.1177/00048674221114782
,2022, 'Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children', Paediatric and Perinatal Epidemiology, 36, pp. 726 - 737, http://dx.doi.org/10.1111/ppe.12870
,2022, 'Children's Relative Age and Medicine Treatment for Attention-Deficit/Hyperactivity Disorder Across Australian Jurisdictions with Different School Enrolment Policies', Journal of Child and Adolescent Psychopharmacology, 32, pp. 349 - 357, http://dx.doi.org/10.1089/cap.2022.0032
,2022, 'The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis', Pharmacoepidemiology and Drug Safety, 31, pp. 370 - 378, http://dx.doi.org/10.1002/pds.5395
,2021, 'Medicine treatment of glaucoma in Australia 2012-2019: Prevalence, incidence and persistence', BMJ Open Ophthalmology, 6, pp. e000921, http://dx.doi.org/10.1136/bmjophth-2021-000921
,2021, 'Generating real-world evidence on the quality use, benefits and safety of medicines in australia: History, challenges and a roadmap for the future', International Journal of Environmental Research and Public Health, 18, pp. 13345, http://dx.doi.org/10.3390/ijerph182413345
,2021, 'Variations in Long-term Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000-2019)', British Journal of Clinical Pharmacology, 87, pp. 3706 - 3720, http://dx.doi.org/10.1111/bcp.14798
,2021, 'The changing face of Australian data reforms: Impact on pharmacoepidemiology research', International Journal of Population Data Science, 6, pp. 1418, http://dx.doi.org/10.23889/ijpds.v6i1.1418
,2021, 'Coming to grips with seemingly conflicting results in programme evaluation: The devil's in the detail', BMJ Quality and Safety, 30, pp. 70 - 71, http://dx.doi.org/10.1136/bmjqs-2020-012118
,2020, 'Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia', BMJ Quality and Safety, 29, pp. 365 - 373, http://dx.doi.org/10.1136/bmjqs-2019-009897
,2020, 'Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016', Therapeutic Advances in Gastroenterology, 13, http://dx.doi.org/10.1177/1756284820913743
,